In an office in Bagsværd near Copenhagen, young biotechnologist Lotte Bjerre Knudsen has been made project manager for a promising, but uncertain project of converting the hormone GLP-1 into a drug.
In 1997, Novo Nordisk scientist Lotte Bjerre Knudsen managed to turn the short-lived GLP-1 hormone into a long-acting drug candidate. However, the initial test failed as the dose was set too low.
We are still equipped with these genes of yesterday, but now they are really working against us by trying to preserve a body weight 'setpoint' that is too high in today's environment.
